Cognision published a study reporting that ketamine produces divergent brain effects across patients and showed that the direction of response can be predicted using EEG. The finding positions EEG as a stratification tool for identifying likely responders before treatment begins, a recurring theme in biomarker-guided psychiatry. For Cognision, which builds an EEG-based assessment platform, the work reinforces a measurement role within the expanding interventional psychiatry space.